As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Arcus Biosciences, Inc. The largest reported stake is Gilead Sciences, Inc.'s, at 24.7%. 6 filings are on record since July 15, 2025 (Schedule 13D/A, August 7, 2026).
Sell to companies like Arcus Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Gilead Sciences, Inc. · Sole voting: 31,424,760 · Shared voting: 0 · Sole dispositive: 31,424,760 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-07
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
- · Holder: BlackRock, Inc. · Percent: 10.4% · SCHEDULE 13G/A
- · Holder: Point72 Asset Management, L.P. · Percent: 4.1% · SCHEDULE 13G/A
- · Holder: Gilead Sciences, Inc. · Percent: 25.6% · SCHEDULE 13D/A
Arcus Biosciences, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-15. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 24.7% | 31,424,760 | SCHEDULE 13D/A, 2026-08-07 | 2026-08-05 |
| BlackRock, Inc. | 10.4% | 12,736,927 | SCHEDULE 13G/A, 2026-01-08 | 2025-12-31 |
| Point72 Asset Management, L.P. | 4.1% | 4,332,479 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Arcus Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Arcus Biosciences, Inc. and the records around it.
Arcus Biosciences, Inc. elsewhere on the record
Companies that share a holder
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026), Arcellx, Inc. (Apr 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Arcus Biosciences, Inc.
Get an email when Arcus Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcus Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arcus Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcus Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | 0 | 31,424,760 | 0 | SCHEDULE 13D/A, 2026-08-07 |
The latest filing identifies Arcus Biosciences, Inc. by CUSIP 03969F109 and gives its principal executive office as 3928 Point Eden Way, Hayward, CA 94545 (SCHEDULE 13D/A, 2026-08-07).
Source of funds (Item 3)
Gilead acquired from the Issuer 2,200,000 shares of Common Stock in the Issuer's public offering (the "2020 Public Offering") at the public offering price of $27.50 per share. The 2020 Public Offering was completed on June 2, 2020. The total consideration paid by Gilead for these shares of Common Stock was $60,500,000, and such consideration was obtained from the available cash resources of Gilead.Gilead Sciences, Inc., SCHEDULE 13D/A, 2026-08-07
Purpose of Transaction (Item 4)
Gilead Sciences, Inc.
On May 27, 2020, Gilead and the Issuer entered into an Option, License and Collaboration Agreement (the "Collaboration Agreement") pursuant to with Gilead obtained an exclusive option to acquire an exclusive license to all of the Issuer's current and future clinical programs during the 10-year collaboration term and, for those programs that enter clinical development prior to the end of the collaboration term, for up to an additional three years thereafter. In addition to the Collaboration Agreement, Gilead and the Issuer entered into a Common Stock Purchase Agreement (the "Purchase Agreement"), which was amended and restated on January 31, 2021 to account for the Second Purchase (the "Amended and Restated Purchase Agreement"), on June 27, 2023 to account for the Third Purchase (the "Second Amended and Restated Purchase Agreement"), and on January 29, 2024 to account for the Fourth Purchase (the "Third Amended and Restated Purchase Agreement") and an Investor Rights Agreement (as amended by Amendment No. 1 thereto, which was subsequently amended and restated on January 29, 2024 and August 5, 2026, the "Third Amended and Restated Investor Rights Agreement" and, together with the Third Amended and Restated Purchase Agreement, the "Equity Agreements"), pursuant to which Gilead made the Initial Purchase at the Initial Purchase Price, the Second Purchase at the Second Purchase Price, the Third Purchase at the Third Purchase Price and the Fourth Purchase at the Fourth Purchase …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-07; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | Gilead Sciences, Inc. | 29.7% | SCHEDULE 13D/A |
| 2025-11-05 | Gilead Sciences, Inc. | 25.6% | SCHEDULE 13D/A |
| 2025-11-14 | Point72 Asset Management, L.P. | 4.1% | SCHEDULE 13G/A |
| 2026-01-08 | BlackRock, Inc. | 10.4% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-08-07 | Gilead Sciences, Inc. | 24.7% | SCHEDULE 13D/A |
Questions about who owns Arcus Biosciences, Inc.
Who owns Arcus Biosciences, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Arcus Biosciences, Inc.: Gilead Sciences, Inc. (24.7%, Schedule 13D/A, filed 2026-08-07) and BlackRock, Inc. (10.4%, Schedule 13G/A, filed 2026-01-08).
Who are the largest shareholders of Arcus Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Arcus Biosciences, Inc. on this page are Gilead Sciences, Inc. (24.7%) and BlackRock, Inc. (10.4%).
When did Gilead Sciences, Inc. buy into Arcus Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13D/A, filed 2025-07-15, reporting 29.7%; its latest, Schedule 13D/A filed 2026-08-07, reports 24.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Arcus Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.